1stOncology™: Cancer Intelligence Service – Page 15166 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Rubius Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Executive Officer

On June 6, 2018 Rubius Therapeutics, a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, reported the appointment of Pablo J. Cagnoni, M.D., as Chief Executive Officer (Press release, Rubius Therapeutics, JUN 6, 2018, View Source [SID1234527211]). Torben Straight Nissen, Rubius’ President, will partner with Dr. Cagnoni to continue to advance the company’s pipeline and other business objectives.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"Pablo’s deep industry expertise and role in the development and commercialization of more than 20 life-changing treatments positions him to lead Rubius as we continue to advance a new class of medicines to treat cancer, autoimmune diseases and rare diseases," said David Epstein, Chairman of Rubius Therapeutics. "We are extremely pleased to welcome Pablo as CEO."

Over the course of Dr. Cagnoni’s career as an oncologist and pharmaceutical executive, he has played a key role in the development, approval and commercialization of several transformative medicines, including Afinitor, Kyprolis and Tarceva. He most recently served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing novel treatments for cancer. Prior to Tizona, Dr. Cagnoni served as President of Onyx Pharmaceuticals, Global Head of Clinical Development at Novartis Oncology, and Chief Medical Officer at Allos Therapeutics and OSI Pharmaceuticals, respectively. Dr. Cagnoni received his M.D. from the University of Buenos Aires School of Medicine, and completed fellowships in Hematology and Oncology at the Mount Sinai Medical Center, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

"I am honored to join Rubius as CEO to continue building the company’s broad and diverse pipeline of Red Cell Therapeutics in multiple therapeutic areas, while making a significant impact for patients with serious diseases," said Dr. Cagnoni. "I look forward to partnering with Torben and the entire team

Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference

On June 6, 2018 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2018 JMP Securities Life Sciences Conference taking place June 20-21 at the St. Regis Hotel in New York, NY (Press release, Protagonist, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353461 [SID1234527210]). The Protagonist Therapeutics presentation is scheduled for Wednesday, June 20, at 2 p.m. EDT.

A live and archived webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics corporate website at View Source

Jefferies Global Healthcare Conference Presentation, dated June 2018.

On June 6, 2018 Pieris Pharmaceuticals, Inc. presented the Jefferies Global Healthcare Conference presentation of Pieris Pharmaceuticals, Inc (Presentation, Pieris Pharmaceuticals, JUN 6, 2018, View Source [SID1234527206]).

Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa

On June 6, 2018 Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that has entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732 (Press release, Moleculin, JUN 6, 2018, View Source [SID1234527205]).

"WP1732, which we believe, based on preclinical testing, is a breakthrough discovery, is now advancing to the stage of formulation development," commented Walter Klemp, Moleculin’s Chairman and CEO. "With the demand for clinical testing of WP1066 continuing to grow, it is easy to forget that we believe WP1732 represents a major expansion of our STAT3 inhibition capability by providing a highly soluble alternative that is ideally suited for IV administration. This agreement marks the beginning of our creating a preclinical package to submit to the FDA in order to request Investigational New Drug status."

Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference

On June 6, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will be webcasting its corporate presentation at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA (Press release, Jazz Pharmaceuticals, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353592 [SID1234527204]).

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Wednesday, June 13, 2018 at 9:20 a.m. PDT / 5:20 p.m. IST.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at View Source Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at View Source